Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"3SBio ","pharmaFlowCategory":"D","amount":"$23.8 million","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics Closes Series B Financing at CHF 22M to Advance Portfolio of Novel Multi-specific Antibodies in Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics and Kaken Pharmaceutical Form Co-Development Alliance for a Next-Generation Atopic Dermatitis Treatment Option","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Sunshine Guojian Pharmaceutical","pharmaFlowCategory":"D","amount":"$15.2 million","upfrontCash":"Undisclosed","newsHeadline":"Numab and 3SBio\u2019s Sunshine Guojian Expand Partnership to Develop Novel T Cell Engager NM28","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"$276.6 million","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics and Ono Pharmaceutical Enter Development and License Agreement for Multispecific Antibody Candidate Involving Novel Immuno-Oncology Target","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Numab Therapeutics Announces First Patient Dosed in Phase 1 Multiple Ascending Dose (MAD) Study of NM26 for Moderate to Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Numab Therapeutics

    Menu

    Numab Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Numab Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer

              Details:

              Through collaboration, Ono has obtained rights for NM49 from Numab for global development and commercialization, which is a multi-specific antibody designed to activate tumor-associated macrophage phagocytosis for the treatment of cancers.

              Lead Product(s): NM49

              Therapeutic Area: Oncology Product Name: NM49

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Ono Pharmaceutical

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 14, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Numab Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Numab Therapeutics Announces First Patient Dosed in Phase 1 Multiple Ascending Dose (MAD) Study of NM26 for Moderate to Severe Atopic Dermatitis

              Details:

              NM26/NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD). MAD data expected to be reported in mid-2024; Single ascending dose (SAD) cohort in healthy volunteers remains ongoing.

              Lead Product(s): NM26-2198

              Therapeutic Area: Dermatology Product Name: NM26

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 19, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Numab Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program

              Details:

              NM26-2198 is a bi-specific antibody which targets IL-4Rα (type I and type II receptors) and IL-31 for the treatment of moderate-to-severe atopic dermatitis (AD).

              Lead Product(s): NM26-2198

              Therapeutic Area: Dermatology Product Name: NM26-2198

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Kaken Pharmaceuticals

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 15, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Numab Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Numab Therapeutics and Ono Pharmaceutical Enter Development and License Agreement for Multispecific Antibody Candidate Involving Novel Immuno-Oncology Target

              Details:

              Under the terms of the license agreement, Ono acquires intellectual property rights and exclusive global development and commercialization rights for a multispecific antibody targeting a novel immuno-oncology target.

              Lead Product(s): Antibody

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Large molecule

              Partner/Sponsor/Collaborator: Ono Pharmaceutical

              Deal Size: $276.6 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement March 31, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Numab Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Numab and 3SBio’s Sunshine Guojian Expand Partnership to Develop Novel T Cell Engager NM28

              Details:

              Under the agreement, Sunshine Guojian has the right to select up to five antibody molecules including ND021, emerging from the three multispecific antibody programs based on Numab’s R&D platform and has the licenses to develop and commercialize each of the antibody molecules.

              Lead Product(s): ND021

              Therapeutic Area: Oncology Product Name: ND021

              Highest Development Status: Preclinical Product Type: Large molecule

              Recipient: Sunshine Guojian Pharmaceutical

              Deal Size: $15.2 million Upfront Cash: Undisclosed

              Deal Type: Partnership December 14, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Numab Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing

              Details:

              Proceeds will support acceleration and expansion of the clinical development of Numab’s lead program NM21-1480 into multiple cancer indications, and the advancement of the company’s pipeline of multi-specific antibodies in oncology and inflammation, into clinical trials.

              Lead Product(s): NM21-1480

              Therapeutic Area: Oncology Product Name: NM21-1480

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Novo Holdings

              Deal Size: $110.0 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing May 20, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Numab Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Numab Therapeutics and Kaken Pharmaceutical Form Co-Development Alliance for a Next-Generation Atopic Dermatitis Treatment Option

              Details:

              Under the expanded agreement, Kaken receives commercial rights for NM26-2198 in Japan, China, South Korea, Taiwan, Singapore, and Hong Kong, while Numab retains the commercial rights to the US, Europe, and the rest of the world.

              Lead Product(s): NM26-2198

              Therapeutic Area: Dermatology Product Name: NM26-2198

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Kaken Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 13, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Numab Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration

              Details:

              The collaboration with Numab Therapeutics expands Boehringer Ingelheim’s bi- and multi-specific antibody pipeline with two front-runner projects in lung and gastrointestinal (GI) cancer and geographic atrophy (GA).

              Lead Product(s): Multi-specific antibody

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement July 07, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Numab Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Numab Therapeutics Closes Series B Financing at CHF 22M to Advance Portfolio of Novel Multi-specific Antibodies in Immuno-Oncology

              Details:

              With the financing secured, Numab plans to further broaden its proprietary pipeline and accelerate the development for a number of programs towards the clinic.

              Lead Product(s): ND021

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: 3SBio

              Deal Size: $23.8 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing March 09, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY